Oncology Institute (TOI) to Release Quarterly Earnings on Thursday

Oncology Institute (NASDAQ:TOI) will likely be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $143.35 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:30 PM ET.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $141.96 million during the quarter, compared to the consensus estimate of $139.78 million.

Oncology Institute Stock Performance

NASDAQ TOI traded down $0.06 on Tuesday, reaching $4.02. 579,199 shares of the stock traded hands, compared to its average volume of 1,882,697. Oncology Institute has a 12 month low of $2.02 and a 12 month high of $4.88. The company has a market cap of $397.53 million, a price-to-earnings ratio of -7.19 and a beta of 0.33. The company has a fifty day moving average price of $3.13 and a 200-day moving average price of $3.35.

Insider Buying and Selling at Oncology Institute

In other Oncology Institute news, major shareholder Jorey Chernett acquired 20,000 shares of the business’s stock in a transaction dated Thursday, April 9th. The shares were purchased at an average price of $3.10 per share, for a total transaction of $62,000.00. Following the completion of the purchase, the insider directly owned 10,499,358 shares of the company’s stock, valued at $32,548,009.80. The trade was a 0.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mohit Kaushal sold 38,433 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $3.50, for a total transaction of $134,515.50. Following the transaction, the director owned 172,583 shares of the company’s stock, valued at $604,040.50. This represents a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders bought a total of 568,985 shares of company stock worth $1,759,601 over the last ninety days. Insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC purchased a new stake in Oncology Institute during the fourth quarter worth $31,000. Cetera Investment Advisers grew its position in shares of Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after acquiring an additional 4,545 shares during the period. State of Wyoming acquired a new position in Oncology Institute in the 2nd quarter worth about $37,000. Prelude Capital Management LLC purchased a new position in Oncology Institute during the third quarter worth approximately $41,000. Finally, BNP Paribas Financial Markets increased its position in shares of Oncology Institute by 141.0% in the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock valued at $42,000 after buying an additional 7,091 shares in the last quarter. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TOI has been the subject of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price target on shares of Oncology Institute in a report on Monday, March 9th. B. Riley Financial lifted their target price on shares of Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. BTIG Research restated a “buy” rating and set a $7.00 price target on shares of Oncology Institute in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.00.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.